2024
Prevalence and Correlates of Depression and Bipolar Disorder Among Patients Maintained on Methadone and Buprenorphine in Ukraine
Morozova O, Dvoriak V, Dumchev K, Machavariani E, Bromberg D, Dvoriak S, Altice F. Prevalence and Correlates of Depression and Bipolar Disorder Among Patients Maintained on Methadone and Buprenorphine in Ukraine. International Journal Of Mental Health And Addiction 2024, 1-18. DOI: 10.1007/s11469-024-01353-6.Peer-Reviewed Original ResearchCorrelates of depressionBipolar disorderUse disorderPrevalence of psychiatric disordersBurden of mental health disordersCo-occurring disordersAlcohol use disorderSubstance use disordersMental health disordersIntegrated care strategiesCluster randomized trialAnalyzed baseline dataOpioid use disorderPsychiatric disordersMethadone dosageDepression diagnosisStigma levelsPHQ-9Moderate/severe depressionHealth disordersDepressionCare strategiesPhysical healthDrug injectionDisordersPreferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey.
Bromberg D, Madden L, Fraenkel L, Muthulingam D, Rhoades D, Dvoriak S, Dumchev K, Pykalo I, Altice F. Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey. PLOS Global Public Health 2024, 4: e0002725. PMID: 38277422, PMCID: PMC10817130, DOI: 10.1371/journal.pgph.0002725.Peer-Reviewed Original ResearchOpioid agonist therapyWithdrawal symptomsAdverse side effectsAgonist therapySide effectsOpioid use disorderQuality-of-life improvementUse disorderCombined HIVHIV incidenceClinical decision-makingDosing frequencyRespondent-driven samplingOpioidOpioid epidemicAssess preferencesClinical concernPatient preferencesPatientsDelivery strategiesTherapyDisordersHIVPatient concernsWithdrawal
2023
High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
Galvez S, Altice F, Meteliuk A, Ivasiy R, Machavariani E, Farnum S, Fomenko T, Islam Z, Madden L. High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine. Frontiers In Public Health 2023, 11: 1231581. PMID: 38098837, PMCID: PMC10720365, DOI: 10.3389/fpubh.2023.1231581.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderAgonist therapyOAT patientsCOVID-19 pandemicSubstance useTake-home dosingAdditional psychosocial supportHigher perceived stressHigh riskPerceived Stress ScalePsychiatric disordersUse disordersPatientsPatient stressPsychosocial supportCertain subgroupsSevere levelsHigh levelsHealthcare deliveryStress ScalePerceived stressTherapyExtraordinary high levelsDisordersDesign, implementation and preliminary results of a type-2 hybrid cluster-randomized trial of integrating screening and treatment for major depressive disorder into specialty clinics providing opioid agonist therapies in Ukraine
Machavariani E, Bromberg D, Dumchev K, Dvoriak S, Zeziulin O, Morozova O, Esserman D, Pykalo I, Saichuk N, Ivasiy R, Haddad M, Altice F. Design, implementation and preliminary results of a type-2 hybrid cluster-randomized trial of integrating screening and treatment for major depressive disorder into specialty clinics providing opioid agonist therapies in Ukraine. Contemporary Clinical Trials 2023, 131: 107248. PMID: 37263492, PMCID: PMC10527419, DOI: 10.1016/j.cct.2023.107248.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyMajor depressive disorderCo-occurring disordersAgonist therapyDepressive disorderSpecialty clinicPsychiatric disordersPatient-level outcomesPrevalent psychiatric disordersCluster-randomized trialPoor health outcomesProvider-level dataMDD treatmentTreatment algorithmExperimental armHigh prevalenceDelivery outcomesHealth outcomesSerial surveysClinicPatientsProject ECHOSubstance useMonthsDisorders
2022
Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection
Eller AJ, DiDomizio EE, Madden LM, Oliva JD, Altice FL, Johnson KA. Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection. Annals Of Medicine 2022, 54: 1714-1724. PMID: 35775786, PMCID: PMC9377256, DOI: 10.1080/07853890.2022.2084154.Peer-Reviewed Original ResearchConceptsCascade of careHuman immunodeficiency virusOpioid use disorderHepatitis C virusPublic health planningUse disordersCo-occurring opioid use disorderHealth planningBurden of diseaseSystems of careQuality improvement activitiesOUD cascadeTreatment initiationImmunodeficiency virusC virusPatient outcomesTreatment accessPayer sourceTreatment retentionHealth systemHealthcare systemCareSyndemicDisordersVirusPregnant Women and Opioid Use Disorder: Examining the Legal Landscape for Controlling Women's Reproductive Health.
Madden L, Oliva J, Eller A, DiDomizio E, Roosa M, Blanchard L, Kil N, Altice F, Johnson K. Pregnant Women and Opioid Use Disorder: Examining the Legal Landscape for Controlling Women's Reproductive Health. American Journal Of Law & Medicine 2022, 48: 209-222. PMID: 36715261, DOI: 10.1017/amj.2022.26.Peer-Reviewed Original ResearchConceptsOpioid use disorderReproductive healthPregnant womenUse disordersPregnant women's useEvidence-based treatmentsReproductive health outcomesWomen's reproductive healthIntersection of HIVSystems of careHealth care choicesPostpartum womenChild healthTreatment policyUnintentional pregnancyHealth outcomesLarger studyWomenTransactional sexCare choicesMinority womenOutcomesOUDWomen's useDisordersA pilot implementation study to scale-up methadone in incarcerated persons with opioid use disorder and retain them on treatment after release in Moldova
Dorgay CE, Bromberg DJ, Doltu S, Litz T, Galvez S, Polonsky M, Dvoryak S, Altice FL. A pilot implementation study to scale-up methadone in incarcerated persons with opioid use disorder and retain them on treatment after release in Moldova. International Journal Of Drug Policy 2022, 104: 103683. PMID: 35417790, PMCID: PMC9827420, DOI: 10.1016/j.drugpo.2022.103683.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentOpioid use disorderUse disordersBrief interventionPilot implementation studySBIRT interventionTreatment initiationMaintenance treatmentMethadonePotential implementation strategiesIncarcerated personsInterventionImplementation studyTreatment proceduresBaselineDisordersTreatmentParticipantsDays of releaseReleaseImplementation strategiesPre-trial detention facilitySessionsHIVReferral
2020
Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults
Viera A, Bromberg DJ, Whittaker S, Refsland BM, Stanojlović M, Nyhan K, Altice FL. Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults. Epidemiologic Reviews 2020, 42: 41-56. PMID: 32239206, PMCID: PMC8087870, DOI: 10.1093/epirev/mxaa001.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersYoung adultsAssociation of ageFull-text reviewRetention of adolescentsConcurrent substance useNegative health outcomesMOUD retentionOpioid epidemicInclusion criteriaHealth outcomesYounger ageAge groupsMOUDSubstance useAdherenceGood evidenceAdultsMedicationsDisordersAdolescentsSearch criteriaAgeOutcomes
2018
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppressionPerceptions of Health-Related Community Reentry Challenges among Incarcerated Drug Users in Azerbaijan, Kyrgyzstan, and Ukraine
Rozanova J, Morozova O, Azbel L, Bachireddy C, Izenberg JM, Kiriazova T, Dvoryak S, Altice FL. Perceptions of Health-Related Community Reentry Challenges among Incarcerated Drug Users in Azerbaijan, Kyrgyzstan, and Ukraine. Journal Of Urban Health 2018, 95: 508-522. PMID: 29728898, PMCID: PMC6095752, DOI: 10.1007/s11524-018-0256-4.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentSubstance use disordersUse disordersMethadone treatmentDrug usersPoor general healthGeneral health conditionPerception of healthAgonist treatmentDrug injectionGeneral healthHigh prevalenceHealth needsHealth-related tasksLogistic regressionMethadoneHealth conditionsPre-release planningDisordersTreatmentPublic healthTotal samplePrison settingDrugsHealthExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomes
2017
Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine
Marcus R, Makarenko I, Mazhnaya A, Zelenev A, Polonsky M, Madden L, Filippovych S, Dvoriak S, Springer SA, Altice FL. Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug And Alcohol Dependence 2017, 179: 213-219. PMID: 28806638, PMCID: PMC5599372, DOI: 10.1016/j.drugalcdep.2017.07.010.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderExtended-release naltrexoneXR-NTXHIV preventionIndependent correlatesPatient preferencesUse disordersShort-term injectorsPatient-centered treatmentAgonist therapyPharmacological therapyHIV incidenceTreatment optionsPWIDTreatment entryAddiction treatmentPreventionNaltrexoneShort durationTherapyNegative attitudesDisordersNew optionsTreatmentA qualitative assessment of an abstinence-oriented therapeutic community for prisoners with substance use disorders in Kyrgyzstan
Azbel L, Rozanova J, Michels I, Altice FL, Stöver H. A qualitative assessment of an abstinence-oriented therapeutic community for prisoners with substance use disorders in Kyrgyzstan. Harm Reduction Journal 2017, 14: 43. PMID: 28693573, PMCID: PMC5504733, DOI: 10.1186/s12954-017-0168-8.Peer-Reviewed Original ResearchConceptsUse disordersDrug useMethadone maintenance therapy programInjection drug useOpioid use disorderTherapeutic communitySubstance use disordersAddiction treatment outcomesCommunity staff membersLack of evidenceMethadone patientsTreatment optionsTreatment outcomesFuture treatmentTherapy programEvidence baseConvenience samplePatientsHigh rateLack of servicesPost-release programsPolicy documentsDisordersResultsOur analysisParticipant observation
2016
The Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Health-Related Quality of Life among Incarcerated, HIV-Infected, Opioid Dependent Malaysian Men: A Moderated Mediation Analysis
Shrestha R, Weikum D, Copenhaver M, Altice FL. The Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Health-Related Quality of Life among Incarcerated, HIV-Infected, Opioid Dependent Malaysian Men: A Moderated Mediation Analysis. AIDS And Behavior 2016, 21: 1070-1081. PMID: 27544515, PMCID: PMC5318281, DOI: 10.1007/s10461-016-1526-3.Peer-Reviewed Original ResearchConceptsAlcohol use disorderNeurocognitive impairmentUse disordersMalaysia's largest prisonHealth-related qualityNeuropsychological factorsQuality of lifeLargest prisonHIV-InfectedOpioid dependenceHIV treatmentHRQoLImportant negative predictorMeeting criteriaFuture interventionsDepressionNegative predictorPLWHDisordersMalaysian menStandardized scalesImpairmentMediation analysisHRQoL.HIVDeterminants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine
Makarenko I, Mazhnaya A, Polonsky M, Marcus R, Bojko MJ, Filippovych S, Springer S, Dvoriak S, Altice FL. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Drug And Alcohol Dependence 2016, 165: 213-220. PMID: 27370527, PMCID: PMC5094181, DOI: 10.1016/j.drugalcdep.2016.06.011.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentAdjusted odds ratioOpioid use disorderAgonist treatmentUse disordersSignificant adjusted odds ratiosMultivariable logistic regressionHIV-negative statusPatient-level interventionsOpioid-dependent peopleInjection frequencyHIV statusOdds ratioRecent overdoseIndependent factorsPWIDLogistic regressionPrevious imprisonmentHigher injection frequencySignificant correlatesPrior incarcerationFamily supportDisordersDrugsIntervention
2013
Being Unaware of Being HIV-Infected is Associated with Alcohol Use Disorders and High-Risk Sexual Behaviors Among Men Who have Sex with Men in Peru
Vagenas P, Ludford KT, Gonzales P, Peinado J, Cabezas C, Gonzales F, Lama JR, Sanchez J, Altice FL, for the Peruvian HIV Sentinel Surveillance Working Group. Being Unaware of Being HIV-Infected is Associated with Alcohol Use Disorders and High-Risk Sexual Behaviors Among Men Who have Sex with Men in Peru. AIDS And Behavior 2013, 18: 120-127. PMID: 23670711, PMCID: PMC3796203, DOI: 10.1007/s10461-013-0504-2.Peer-Reviewed Original ResearchConceptsAlcohol use disorderHigh-risk sexual behaviorHIV infectionUse disordersMultivariate logistic regressionUnprotected anal intercourseSexual behaviorHIV-InfectedHIV statusSyphilis testingHIV riskAnal intercourseTherapy interventionHIVLogistic regressionMenLast encounterSexInfectionDisordersParticipantsRisk assessmentMSMPeruvian citiesMonthsAlcohol use disorders and antiretroviral therapy among prisoners in Argentina
Alpert M, Wickersham JA, Vázquez M, Altice FL. Alcohol use disorders and antiretroviral therapy among prisoners in Argentina. International Journal Of Prison Health 2013, 9: 40-50. PMID: 24772187, PMCID: PMC3999974, DOI: 10.1108/17449201311310797.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAntiretroviral therapyUse disordersSecondary HIV preventionCent of subjectsCross-sectional surveyHIV careSubstance abuse patternsMajority of participantsIndependent correlatesHIV preventionTreatment outcomesGeneral populationHIVHealth care reformAbuse patternsAUDIT scaleCurrent incarcerationDisordersTherapyOne-thirdCare reformOne-quarterParticipantsFuture efforts
2007
Pharmacological pain control for human immunodeficiency virus–infected adults with a history of drug dependence
Basu S, Bruce RD, Barry DT, Altice FL. Pharmacological pain control for human immunodeficiency virus–infected adults with a history of drug dependence. Journal Of Substance Use And Addiction Treatment 2007, 32: 399-409. PMID: 17481463, PMCID: PMC2128698, DOI: 10.1016/j.jsat.2006.10.005.Peer-Reviewed Original ResearchConceptsSubstance use disordersPharmacological pain controlChronic pain conditionsUse disordersPain controlPain conditionsHuman immunodeficiency virus-infected adultsAberrant drug-taking behaviorsHIV-specific issuesComplaints of painPain management servicesHuman immunodeficiency virusTreatment of painEvidence-based guidanceDrug-taking behaviorClinical reviewImmunodeficiency virusDrug interactionsPatientsDrug dependenceHIVPainDisordersCliniciansPhysicians